{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:13:12Z","timestamp":1785510792944,"version":"3.56.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1999,12,1]],"date-time":"1999-12-01T00:00:00Z","timestamp":944006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[1999,12]]},"DOI":"10.1016\/s0016-5085(99)70277-5","type":"journal-article","created":{"date-parts":[[2005,11,30]],"date-time":"2005-11-30T19:57:23Z","timestamp":1133380643000},"page":"1278-1287","source":"Crossref","is-referenced-by-count":236,"title":["An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease"],"prefix":"10.1016","volume":"117","author":[{"given":"Eric A.","family":"Vasiliauskas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Y.","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Abreu-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip V.","family":"Hassard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas A.","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome B.","family":"Zeldis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan R.","family":"Targan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0016-5085(99)70277-5_bib1","first-page":"487","article-title":"Glucocorticoids","author":"Andus","year":"1993"},{"key":"10.1016\/S0016-5085(99)70277-5_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJM199603283341307","article-title":"Inflammatory bowel disease","volume":"334","author":"Hanauer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/S0016-5085(99)70277-5_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ibd.3780010107","article-title":"A critical review of cyclosporine therapy in inflammatory bowel disease","volume":"1","author":"Sandborn","year":"1995","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/S0016-5085(99)70277-5_bib4","first-page":"A851","article-title":"Continuous infusion cyclosporine (CSA) is effective for severe acute Crohn's disease (CD). . .but for how long","volume":"110","author":"Abreu-Martin","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/S0016-5085(99)70277-5_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","article-title":"Tumor necrosis factor and Crohn's disease","volume":"40","author":"Van Deventer","year":"1997","journal-title":"Gut"},{"key":"10.1016\/S0016-5085(99)70277-5_bib6","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor \u03b1\u2013producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/S0016-5085(99)70277-5_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2249.1990.tb03334.x","article-title":"Tumor necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine","volume":"81","author":"MacDonald","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/S0016-5085(99)70277-5_bib8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/gut.34.12.1705","article-title":"Location of tumour necrosis factor \u03b1 by immunohistochemistry in chronic inflammatory bowel disease","volume":"34","author":"Murch","year":"1993","journal-title":"Gut"},{"key":"10.1016\/S0016-5085(99)70277-5_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti\u2013tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/S0016-5085(99)70277-5_bib10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/S0016-5085(99)70277-5_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP57l antibody to tumour necrosis factor\u2013\u03b1 in Crohn's disease","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S0016-5085(99)70277-5_bib12","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/S0016-5085(99)70277-5_bib13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","article-title":"Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0016-5085(99)70277-5_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ibd.3780050209","article-title":"Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety","volume":"5","author":"Sandborn","year":"1999","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/S0016-5085(99)70277-5_bib15","first-page":"A731","article-title":"Delayed hypersensitivity to infliximab (Remicadet\u00ae) re-infusion after a 2-4 year interval without treatment (abstr)","volume":"116","author":"Hanauer","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/S0016-5085(99)70277-5_bib16","first-page":"719","article-title":"WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients","volume":"45","author":"Iyer","year":"1971","journal-title":"Bull World Health Organ"},{"key":"10.1016\/S0016-5085(99)70277-5_bib17","first-page":"26","article-title":"An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum","volume":"42","author":"Waters","year":"1971","journal-title":"Lepr Rev"},{"key":"10.1016\/S0016-5085(99)70277-5_bib18","series-title":"Sixth Report","author":"WHO Expert Committee on Leprosy","year":"1988"},{"key":"10.1016\/S0016-5085(99)70277-5_bib19","first-page":"158","article-title":"Treatment of refractory rheumatoid arthritis\u2014the thalidomide experience","volume":"16","author":"Guti\u00e9rrez-Rodr\u00edguez","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/S0016-5085(99)70277-5_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2796.1990.tb00253.x","article-title":"Treatment of severe colitis in Beh\u00e7et's syndrome with thalidomide (CG-217)","volume":"228","author":"Larsson","year":"1990","journal-title":"J Intern Med"},{"key":"10.1016\/S0016-5085(99)70277-5_bib21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0016-5085(99)70277-5_bib22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on TNF-\u03b1 by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/S0016-5085(99)70277-5_bib23","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.4049\/jimmunol.159.10.5157","article-title":"Inhibition of IL-12 production by thalidomide","volume":"159","author":"Moller","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/S0016-5085(99)70277-5_bib24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1749-6632.1996.tb52695.x","article-title":"Effect of IL-12 and antibodies to IL-12 on established granulomatous colitis in mice","volume":"795","author":"Neurath","year":"1996","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/S0016-5085(99)70277-5_bib25","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(05)64206-7","article-title":"Thalidomide in Crohn's disease","volume":"350","author":"Wettstein","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S0016-5085(99)70277-5_bib26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005176-199708000-00032","article-title":"Thalidomide in oral Crohn's disease refractory to conventional medical treatment","volume":"25","author":"Odeka","year":"1997","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/S0016-5085(99)70277-5_bib27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00005176-199902000-00025","article-title":"Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease","volume":"28","author":"Weinstein","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/S0016-5085(99)70277-5_bib28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","article-title":"Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses","volume":"35","author":"Tseng","year":"1996","journal-title":"J Am Acad of Dermatol"},{"key":"10.1016\/S0016-5085(99)70277-5_bib29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM199204163261604","article-title":"Thalidomide for the treatment of chronic graft-versus-host disease","volume":"326","author":"Vogelsang","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/S0016-5085(99)70277-5_bib30","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.V86.9.3604.bloodjournal8693604","article-title":"Thalidomide as salvage therapy for chronic graft-versus-host disease","volume":"86","author":"Parker","year":"1995","journal-title":"Blood"},{"key":"10.1016\/S0016-5085(99)70277-5_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jnnp.31.6.543","article-title":"Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study","volume":"31","author":"Fullerton","year":"1968","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0016-5085(99)70277-5_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2133.1985.tb02323.x","article-title":"Development of polyneuropathy during thalidomide therapy","volume":"112","author":"Wulff","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/S0016-5085(99)70277-5_bib33","first-page":"A283","article-title":"Thalidomide\u2013induced neuropathy: clinical and eletrophysiological features","volume":"46","author":"Chaudhry","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/S0016-5085(99)70277-5_bib34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0016-5085(79)90384-6","article-title":"Rederived values of the eight co-efficients of the Crohn's Disease Activity Index (CDAI)","volume":"77","author":"Best","year":"1979","journal-title":"Gastro-enterology"},{"key":"10.1016\/S0016-5085(99)70277-5_bib35","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM196212132672407","article-title":"The saga of thalidomide (concluded): neuropathy to embryopathy, with case reports of congenital anomalies","volume":"24","author":"Mellin","year":"1962","journal-title":"N Engl J Med"},{"key":"10.1016\/S0016-5085(99)70277-5_bib36","first-page":"226","article-title":"Teratogens","author":"Manson","year":"1991"},{"key":"10.1016\/S0016-5085(99)70277-5_bib37","series-title":"Thalomid (thalodomide)","year":"1999"},{"key":"10.1016\/S0016-5085(99)70277-5_bib38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/S0016-5085(99)70277-5_bib39","first-page":"A745","article-title":"Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD)","volume":"116","author":"Kane","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/S0016-5085(99)70277-5_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2165\/00002018-199207020-00004","article-title":"Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations","volume":"7","author":"G\u00fcnzler","year":"1992","journal-title":"Drug Saf"},{"key":"10.1016\/S0016-5085(99)70277-5_bib41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mus.880090907","article-title":"Thalidomide neuropathy: an electrophysiologic study","volume":"9","author":"Lagueny","year":"1986","journal-title":"Muscle Nerve"},{"key":"10.1016\/S0016-5085(99)70277-5_bib42","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0140-6736(91)91221-F","article-title":"Thalidomide hypersensitivity in AIDS","volume":"337","author":"Williams","year":"1991","journal-title":"Lancet"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508599702775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508599702775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T17:40:52Z","timestamp":1683308452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508599702775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["S0016508599702775"],"URL":"https:\/\/doi.org\/10.1016\/s0016-5085(99)70277-5","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[1999,12]]}}}